| Literature DB >> 29922077 |
Andrés Martín-Aspas1, Francisca M Guerrero-Sánchez1, Francisco García-Colchero1, Sebastián Rodríguez-Roca1, José-Antonio Girón-González1.
Abstract
OBJECTIVES: The objectives of this study were to detect those characteristics that were specifically associated with infection or colonization by Acinetobacter baumannii, describe the clinical manifestations of those patients in whom the infection was detected in intensive care unit (ICU) or non-ICU wards, and analyze the prognosis-associated factors in patients from whom A. baumannii was isolated. PATIENTS AND METHODS: A sample of 122 patients from whom A. baumannii was recovered during an endemic period in a teaching hospital was included. Only those cases in which A. baumannii was recovered as the unique microbe were considered. Demographic data; ward of admission; intrinsic and extrinsic risk factors for infection or colonization; chronic underlying condition severity, as evaluated by the McCabe classification or Charlson index and Acute Physiology and Chronic Health Evaluation (APACHE) II score; and clinical manifestations were analyzed to differentiate specific characteristics of colonized or infected patients. Factors independently associated with the mortality at 30 days were also analyzed by Cox regression.Entities:
Keywords: Acinetobacter baumannii; care unit; colonization; infection; mortality; pneumonia; tracheobronchitis
Year: 2018 PMID: 29922077 PMCID: PMC5995284 DOI: 10.2147/IDR.S163944
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Figure 1Diagram showing excluded and included patients in the study.
Note: As one patient usually had more than one culture and isolation, total number of isolates in each group is shown.
Abbreviation: A. baumannii, Acinetobacter baumannii.
Differential characteristics between colonized and infected individuals, by A. baumannii (n=122)
| Parameter | Colonized patients (n=73) | Infected patients (n=49) | Multivariant analysis
| ||
|---|---|---|---|---|---|
| Exp(B) (95% CI) | |||||
| Age (years), mean ± standard deviation | 65±15 | 55±18 | 0.002 | ||
| Sex (male), n (%) | 44 (60) | 39 (80) | 0.030 | ||
| Present admission at ICU, n (%) | 27 (37) | 32 (65) | 0.002 | 4.55 (1.79–11.53) | 0.001 |
| Previous admission at ICU, n (%) | 42 (57) | 43 (88) | <0.001 | ||
| Length of stay previous to isolation of | 22±19 | 31±36 | 0.049 | 1.02 (1.01–1.04) | 0.012 |
| Presence of intrinsic risk factors (chronic underlying condition), n (%) | 65 (89) | 30 (61) | 0.001 | ||
| McCabe classification, n (%) | 0.001 | ||||
| Non-fatal | 31 (43) | 37 (76) | 2.94 (1.26–2.89) | 0.013 | |
| Ultimately or rapidly fatal | 42 (58) | 12 (24) | |||
| Charlson index, mean ± standard deviation | 2.95±2.34 | 1.31±2.05 | <0.001 | ||
| APACHE II score | 22±8 | 23±9 | 0.309 | ||
| Presence of extrinsic risk factors, n (%) | |||||
| Central venous catheter | 50 (69) | 40 (82) | 0.142 | ||
| Urinary catheter | 55 (75) | 43 (88) | 0.108 | ||
| Parenteral nutrition | 7 (10) | 2 (4) | 0.312 | ||
| Enteral nutrition | 27 (37.0) | 34 (69.4) | 0.001 | ||
| Mechanical ventilation | 25 (34.2) | 26 (53.1) | 0.042 | ||
| Tracheostomy | 6 (8.2) | 13 (26.5) | 0.010 | ||
| Major surgical procedure | 26 (35.6) | 13 (26.5) | 0.327 | ||
| Cerebrospinal fluid derivation | 5 (7) | 11 (22) | 0.402 | ||
| Digestive endoscopy in previous week | 0 | 2 (4) | 0.159 | ||
| Antibiotic therapy in the previous 90 days | 70 (96) | 46 (94) | 0.683 | ||
| Treatment with carbapenems in the previous 90 days | 29 (40) | 20 (41) | 1.000 | ||
| Isolation sites for | <0.001 | ||||
| Sputum | 6 (8) | 7 (14) | |||
| Tracheal aspirate | 26 (36) | 36 (74) | |||
| Blood | 0 (0) | 3 (6) | |||
| Urine | 10 (14) | 0 (0) | |||
| Ascitic fluid | 2 (3) | 1 (2) | |||
| Surgical wound | 18 (25) | 1 (2) | |||
| Others | 11 (15) | 1 (2) | |||
| Resistance pattern, n (%) | 0.081 | ||||
| Susceptible | 3 (4) | 0 | |||
| Multidrug resistant | 18 (25) | 6 (12) | |||
| Extensively resistant | 52 (71) | 42 (86) | |||
| Pandrug resistant | 0 (0) | 1 (2) | |||
Notes:
The presence of cardiac (colonized, 30 [41%] patients; infected, seven [14%] cases; p=0.002) and respiratory (colonized, 21 [29%] patients; infected, four [8%] cases; p=0.006) chronic underlying conditions was significantly more frequent in colonized individuals. The rest of the intrinsic risk factors did not show significant differences between both groups.
APACHE II was measured only in patients in ICU (n=59; colonized, 27 cases; infected, 32 cases).
Abbreviations: A. baumannii, Acinetobacter baumannii; CI, confidence interval; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation.
Characteristics of patients infected by A. baumannii (n=49) according to the ward of hospitalization (ICU vs non-ICU)
| Parameter | ICU (n=32) | Non-ICU (n=17) | |
|---|---|---|---|
| Age (years), mean ± standard deviation | 54±16 | 56±22 | 0.377 |
| Sex (male), n (%) | 23 (72) | 16 (94) | 0.066 |
| Presence of intrinsic risk factors (chronic underlying conditions), n (%) | 14 (44) | 16 (94) | 0.001 |
| McCabe classification, n (%) | 0.007 | ||
| Non-fatal | 28 (88) | 9 (53) | |
| Ultimately or rapidly fatal | 4 (12) | 8 (47) | |
| Charlson index, mean ± standard deviation | 0.84±1.51 | 2.18±2.65 | 0.012 |
| Sites of infection, n (%) | 0.001 | ||
| Pneumonia | 25 (78) | 2 (12) | |
| Tracheobronchitis | 6 (19) | 10 (59) | |
| Primary bacteremia | 1 (3) | 2 (12) | |
| Surgery-related intra-abdominal | 0 | 1 (6) | |
| Osteoarticular | 0 | 1 (6) | |
| Soft tissue | 0 | 1 (6) | |
| Secondary bacteremia | 5 (16) | 1 (6) | |
| Severity of infection, n (%) | 0.131 | ||
| Sepsis | 22 (69) | 15 (92) | |
| Severe sepsis/septic shock | 10 (31) | 2 (12) | |
| Combination antibiotherapy, n (%) | 16 (50) | 12 (71) | 0.229 |
| Mortality at 30 days, n (%) | 7 (22) | 6 (35) | 0.331 |
Abbreviations: A. baumannii, Acinetobacter baumannii; ICU, intensive care unit.
Factors associated with survival in a series of hospitalized patients colonized or infected by A. baumannii (n=122)
| Parameter | Survivors (n=93) | Non-survivors (n=29) | Multivariant analysis
| ||
|---|---|---|---|---|---|
| Exp(B) (95% CI) | |||||
| Age (years), mean ± standard deviation | 59±18 | 66±12 | 0.035 | ||
| Sex (male), n (%) | 62 (66.7) | 21 (72.4) | 0.652 | ||
| Present admission at ICU, n (%) | 45 (48) | 14 (48) | 1.000 | ||
| Length of stay previous to isolation of | 28±30 | 19±15 | 0.127 | ||
| mean ± standard deviation | |||||
| Presence of intrinsic risk factors (chronic underlying conditions), n (%) | 67 (72) | 28 (97) | 0.004 | ||
| McCabe classification, n (%) | <0.001 | ||||
| Non-fatal | 60 (65) | 8 (28) | 2.44 (1.05–5.66) | 0.039 | |
| Ultimately or rapidly fatal | 33 (35) | 21 (72) | |||
| Charlson index, mean ± standard deviation | 1.87±2.28 | 3.62±2.87 | <0.001 | ||
| APACHE II score | 21±7 | 26±6 | 0.013 | ||
| Presence of extrinsic risk factors, n (%) | |||||
| Central venous catheter | 68 (73) | 22 (76) | 1.000 | ||
| Urinary catheter | 76 (82) | 22 (76) | 0.593 | ||
| Parenteral nutrition | 6 (7) | 3 (10) | 0.442 | ||
| Enteral nutrition | 45 (48) | 16 (55) | 0.671 | ||
| Mechanical ventilation | 37 (40) | 14 (48) | 0.518 | ||
| Tracheostomy | 15 (16) | 4 (14) | 1.000 | ||
| Major surgical procedure | 33 (36) | 6 (21) | 0.173 | ||
| Cerebrospinal fluid derivation | 12 (13) | 4 (14) | 0.753 | ||
| Digestive endoscopy in the previous week | 1 (1) | 1 (3) | 0.420 | ||
| Antibiotic therapy in the previous 90 days | 88 (95) | 28 (97) | 1.000 | ||
| Treatment with carbapenems in the previous 90 days | 39 (43) | 10 (35) | 0.517 | ||
| Isolation sites for | 0.171 | ||||
| Sputum | 8 (9) | 5 (17) | |||
| Tracheal aspirate | 46 (50) | 16 (55) | |||
| Blood | 2 (2) | 1 (3) | |||
| Urine | 7 (8) | 3 (10) | |||
| Ascitic fluid | 1 (1) | 2 (7) | |||
| Surgical wound | 18 (19) | 1 (3) | |||
| Others | 10 (11) | 1 (3) | |||
| Resistance pattern, n (%) | 0.074 | ||||
| Susceptible | 2 (2) | 1 (3) | |||
| Multidrug resistant | 23 (25) | 1 (3) | |||
| Extensively resistant | 66 (72) | 27 (93) | |||
| Pandrug resistant | 1 (1) | 0 | |||
| Infected patients, n (%) | 36 (39) | 13 (45) | 0.665 | 2.75 (1.18–6.38) | 0.019 |
Notes:
The presence of liver disease (survivors, four (4%) patients; non-survivors, five (17%) cases; p=0.034), cardiac failure (survivors, 23 (25%) patients; non-survivors, 14 (48%) cases; p=0.021), and immune depression (survivors, 11 (12%) patients; non-survivors, 12 (41%) cases; p=0.001) was significantly less frequent in survivors. The rest of the intrinsic risk factors did not show significant differences between both groups.
APACHE II was measured only in patients in ICU (n=59).
Abbreviations: A. baumannii, Acinetobacter baumannii; CI, confidence interval; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation.
Figure 2Kaplan–Meier curves plotting the survival of patients colonized or infected with A. baumannii (n=122), based on (A) McCabe classification: non-fatal class (dashed line) or rapidly or ultimately fatal (continuous line) and (B) colonization (dashed line) or infection (continuous line) by A. baumannii.
Abbreviation: A. baumannii, Acinetobacter baumannii.
Factors associated with survival in a series of hospitalized patients infected by A. baumannii (n=49)
| Parameter | Survivors (n=36) | Non-survivors (n=13) | |
|---|---|---|---|
| Age (years), mean ± standard deviation | 50±18 | 69±10 | <0.001 |
| Sex (male), n (%) | 29 (81) | 10 (77) | 1.000 |
| Present admission at ICU, n (%) | 25 (70) | 7 (54) | 0.331 |
| Length of hospital stay previous to isolation of | 35±40 | 21±18 | 0.209 |
| Presence of intrinsic risk factors (basal disease), n (%) | 18 (50) | 12 (92) | 0.008 |
| McCabe classification, n (%) | <0.001 | ||
| Non-fatal | 33 (92) | 4 (31) | |
| Ultimately or rapidly fatal | 3 (8) | 9 (69) | |
| Charlson index, mean ± standard deviation | 0.56±0.81 | 3.38±2.93 | <0.001 |
| APACHE II score | 21±8 | 31±10 | 0.029 |
| Respiratory infection vs others, n (%) | 32 (89) | 11 (86) | 0.687 |
| Severe sepsis/septic shock, n (%) | 6 (17) | 6 (46) | 0.058 |
| Resistance pattern, n (%) | 0.687 | ||
| Multidrug resistant | 5 (14) | 1 (8) | |
| Extensively resistant | 30 (83) | 12 (92) | |
| Pandrug resistant | 1 (3) | 0 (0) | |
| Combination antibiotherapy, n (%) | 22 (61) | 6 (46) | 0.514 |
Note:
APACHE II was measured only in patients in ICU (n=32).
Abbreviations: A. baumannii, Acinetobacter baumannii; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation.